Merus Stock Forecast, Price & News

Merus (NASDAQ:MRUS) Frequently Asked Questions

Is Merus a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Merus stock.
View analyst ratings for Merus or view top-rated stocks.

What stocks does MarketBeat like better than Merus?

Wall Street analysts have given Merus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Merus?

Merus saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 2,690,000 shares, an increase of 26.3% from the July 29th total of 2,130,000 shares. Based on an average daily volume of 276,300 shares, the short-interest ratio is presently 9.7 days. Approximately 8.8% of the shares of the stock are sold short.
View Merus' Short Interest.

When is Merus' next earnings date?

Merus is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Merus.

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.13. The biotechnology company earned $12.38 million during the quarter, compared to the consensus estimate of $7.83 million. Merus had a negative net margin of 231.19% and a negative trailing twelve-month return on equity of 51.93%.
View Merus' earnings history.

How has Merus' stock been impacted by Coronavirus?

Merus' stock was trading at $14.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRUS shares have increased by 52.8% and is now trading at $22.21.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MRUS?

5 brokers have issued 1 year target prices for Merus' shares. Their forecasts range from $21.00 to $33.00. On average, they expect Merus' share price to reach $29.00 in the next twelve months. This suggests a possible upside of 30.6% from the stock's current price.
View analysts' price targets for Merus or view top-rated stocks among Wall Street analysts.

Who are Merus' key executives?

Merus' management team includes the following people:

• Bill Lundberg, President, CEO, CFO & Non-Executive Director
• John de Kruif, Chief Technology Officer & Senior Vice President
• Andrew Joe, Chief Medical Officer
• Liu Hui, Chief Business Officer & Executive Vice President
• Peter B. Silverman, Executive Vice President & General Counsel

Who are some of Merus' key competitors?

Some companies that are related to Merus include Nektar Therapeutics (NKTR), Prothena (PRTA), Cryoport (CYRX), Insmed (INSM), ALX Oncology (ALXO), Intra-Cellular Therapies (ITCI), Aurinia Pharmaceuticals (AUPH), Lyell Immunopharma (LYEL), Amicus Therapeutics (FOLD), Emergent BioSolutions (EBS), Agios Pharmaceuticals (AGIO), Prestige Consumer Healthcare (PBH), Zentalis Pharmaceuticals (ZNTL), PTC Therapeutics (PTCT) and Cytokinetics (CYTK).
View all of MRUS's competitors.

What other stocks do shareholders of Merus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC).

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Who are Merus' major shareholders?

Merus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (7.74%), Avoro Capital Advisors LLC (1.72%), Morgan Stanley (1.08%), Morgan Stanley (1.08%), Deutsche Bank AG (1.02%) and Millennium Management LLC (0.83%). Company insiders that own Merus stock include Bvf Partners L P/Il, Kruif John De, Lex Bakker, Mark Throsby and Value Fund L P Biotechnology.
View institutional ownership trends for Merus.

Which major investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., FMR LLC, Morgan Stanley, Morgan Stanley, Ikarian Capital LLC, Deutsche Bank AG, Credit Suisse AG, and Avoro Capital Advisors LLC. Company insiders that have sold Merus company stock in the last year include Bvf Partners L P/Il, Kruif John De, and Lex Bakker.
View insider buying and selling activity for Merus or view top insider-selling stocks.

Which major investors are buying Merus stock?

MRUS stock was purchased by a variety of institutional investors in the last quarter, including AXA S.A., Sphera Funds Management LTD., Millennium Management LLC, BlackRock Inc., Point72 Asset Management L.P., Citadel Advisors LLC, Marshall Wace LLP, and Marshall Wace LLP. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Merus or or view top insider-buying stocks.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $22.21.

How much money does Merus make?

Merus has a market capitalization of $854.64 million and generates $29.94 million in revenue each year. The biotechnology company earns $-85,510,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How many employees does Merus have?

Merus employs 117 workers across the globe.

What is Merus' official website?

The official website for Merus is www.merus.nl.

Where are Merus' headquarters?

Merus is headquartered at YALELAAN 62, UTRECHT P7, 3584 CM.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at (130) 253-8800 or via email at [email protected].